A $114m diversity in clinical trials initiative supported by the Bristol Myers Squibb Foundation (BMSF) and Gilead Sciences has selected 64 physicians for awards.
The company announces further measures against a counterfeiting network it accused of being responsible for selling illegitimate Gilead HIV medications.
The Biotechnology Innovation Organization elected the fresh slate of leaders during the BIO International Convention, taking place in San Diego this week.
The agency has removed the hold placed on the pharmaceutical company’s IND for injectable lenacapavir, which is intended for HIV treatment and prevention.
The US agency has expanded its approval of Veklury to include use in pediatric patients 28 days and older who have tested positive for the COVID-19 virus.
The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.
The pharma firm reports its Veklury (remdesivir) led to a reduction in mortality rate among hospitalized patients in three analyses of real-world data.
The two major pharmaceutical firms have agreed to jointly develop and commercialize treatment combinations of lenacapavir and islatravir in HIV patients.
The agency has given the go-ahead for use of baricitinib in conjunction with remdesivir for treating patients hospitalized with severe cases of the virus.
The agency has approved the antiviral drug Veklury (remdesivir), produced by Gilead, for hospitalized patients 12 years and over diagnosed with the virus.
After receiving FDA approval, the pharmaceutical company has announced plans to launch a Phase I trial for an inhaled version of the COVID-19 treatment.
Vineti’s latest financing round sees Novartis and Gilead join forces to invest in technology platform that enables scale-up of CAR Ts and allogeneic cell therapies.
US FDA expands the approval of Gilead’s Descovy to make it available for the PrEP indication, coming ahead of the entrance of generic rivals to the company’s Truvada product.
Following Gilead’s funding of Lyndra’s technology, the latter company offers exclusive rights to its therapeutics platform for long-acting HIV therapies formulations.
Gilead and HitGen have signed a drug discovery collaboration – one of several recently announced agreements as HitGen sees increased demand for its technology, says CSO.
As generic competition looms, Gilead donates 2.4 million bottles of Truvada to the CDC to aid in the center’s fight against the HIV epidemic in the US.
GSK’s Dovato is approved by the US FDA for the treatment of individuals with HIV with no previous antiretroviral therapy, in a first for a two-drug, fixed-dose, complete regimen.
Securing the clinical supply chain comes down to the notion of ‘compliance’, which is transitioning from a ‘nice to have’ to a ‘need to have,’ says Cryoport.
Gilead says launching generic versions of its pricey hepatitis C drugs more than a decade prior to patent expiries will more closely align product list prices with their cost.
The European Patent Office has upheld protection relating to Gilead’s costly Hepatitis C drug Sovaldi, which Médecins du Monde claims prevents patients from receiving affordable treatment.
The US FDA has released draft guidance documents on gene therapy programmes, which “should help sponsors avoid expending time and resources on unproductive drug development efforts,” says expert.
Gilead has granted seven Indian drugmakers licenses to produce generic versions of its $1,000 a pill drug Sovaldi to increase access to hepatitis C medicines in 91 developing countries.
US-based Gilead Sciences has ditched its plans to build a new €60m
plant in Dublin, Ireland, instead acquiring Nycomed's Irish
manufacturing facility in Cork for almost €34m.
Under pressure to respond to the spread of HIV in the developing
world, Gilead has signed non-exclusive licence agreements with
eight Indian generic companies for the manufacture of Viread
(tenofovir disoproxil fumarate), its popular...
Biotechnology firm Gilead has acquired Raylo Chemicals, a Canadian
production unit of active pharmaceutical ingredients (APIs) and
advanced intermediates, from Degussa for €115m, seeking to bring
more manufacturing capacity and expertise...
